AAT protein restores blood glucose in type 1 diabetes model

The findings, which appear in the Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS) this week, provide further proof that inflammation plays a key role in the development of Type 1 diabetes and suggest that the protein – known as AAT --might be an option for clinical testing in humans.

Formerly known as juvenile-onset or insulin-dependent diabetes, Type 1 diabetes is an autoimmune disease that develops when the body's immune cells (known as T-cells) overreact and attack and destroy its own pancreatic beta cells. Without beta cells, the body is unable to produce insulin, a hormone needed to convert glucose into energy. To prevent the development of serious – and even fatal -- complications, more than 21 million individuals with Type 1 diabetes, primarily children and young adults, must receive as many as three insulin injections each day.

"To cure Type 1 diabetes, it will not be enough to halt the destructive T-cell-dependent autoimmune attack on beta cells," explains the study's lead author Maria Koulmanda, PhD, Director of Non-Human Primate Research in the Transplant Center at Beth Israel Deaconess Medical Center (BIDMC) and Associate Professor of Surgery at Harvard Medical School (HMS). "We think that it will also be necessary to restore proper insulin signaling, and the way to do that is by eliminating the curious inflammatory state that exists in muscle, fat and other insulin-sensitive tissues."

Last year, Koulmanda, together with the paper's senior author Terry Strom, MD, Director of Transplant Research at BIDMC and Professor of Medicine at HMS, established a role for insulin resistance and inflammation in the onset of Type 1 diabetes, a finding that challenged many theories regarding the autoimmune disease. Their findings demonstrated for the first time that a form of inflammation in fat and muscle was preventing insulin from "allowing" blood glucose into tissues requiring glucose. They further demonstrated that normal blood glucose levels could be successfully restored in a non-obese diabetic (NOD) mouse model by administering a triple combination therapy consisting of both tolerance-inducing and anti-inflammatory properties.

In this new paper, Koulmanda borrowed the AAT protein to achieve the same results.

"The AAT protein is made by the liver and functions to halt unchecked inflammation," she explains. "In cases of Type 1 diabetes, inflammation is the factor that determines whether T-cells exert destructive or protective forms of immunity. We, therefore, hypothesized that [in cases of Type 1 diabetes] immune tolerance could be reestablished by using the AAT protein to modify a pro-inflammatory state and turn it into an anti-inflammatory state."

Using the NOD mouse model, the authors tested the hypothesis that inflammatory mechanisms directly trigger insulitis, insulin resistance, faulty insulin signaling and the loss of immune tolerance to islets.

"We were able to demonstrate that treatment with AAT – an agent that dampens inflammation but does not directly inhibit T-cell activation – ablates invasive insulitis and restores euglycemia [normal blood glucose concentration], immune tolerance to beta cells, normal insulin signaling and insulin responsiveness in NOD mice with recent onset Type 1 diabetes," she says.

Most dramatic, adds Koulmanda, their experiments found that the functional mass of beta cells actually expanded in the NOD mice treated with AAT.

The AAT protein is already in widespread use as a replacement therapy in treating Alpha-1 antitrypsin deficiency, an inherited disorder that can cause emphysema-like lung disease in adults and liver disease in children.

"In humans, AAT has been used for more than two decades, and has maintained an impressive safety record," says Koulmanda. "We believe that treatment with AAT will prevent and delay further loss of functioning residual beta cells in patients with recent onset Type 1 diabetes.

"With this study, we've shown that modifications in inflammation indirectly – but powerfully – modify ongoing destructive-type immunity," she adds. "And most exciting, by administering AAT to the diabetic mice, we actually achieved beta cell expansion, which has never been shown with any other treatment."

Source: Beth Israel Deaconess Medical Center

Well-known drug (AAT) could overcome obstacles to islet transplantation
Researchers from Ben-Gurion University of the Negev (BGU) in Beer-Sheva, Israel have demonstrated that treating diabetic animals with alpha-1-antitrypsin (AAT) following an islet transplantation procedure eliminates the inflammation that causes islet transplants to fail. (PNAS Article #08-07627: "Alpha-1-Antitrypsin Monotherapy Induces Immune Tolerance during Islet Allograft Transplantation in Mice") (http://www.pnas.org/content/105/42/16236)
Researcher develops screening tool to identify patients with prediabetes
A third of Americans with diabetes do not know that they have it, and many more who have prediabetic conditions are unaware that they are at risk. A University of Missouri researcher has created a clinical tool to identify those at highest risk for having undetected hyperglycemia, impaired fasting glucose (IFG) and undiagnosed diabetes. If these conditions are identified early, patients may benefit from preventative strategies that can minimize progression to diabetes, other diseases and mortality.
Vitamin E shows possible promise in easing chronic inflammation
With up to half of a person's body mass consisting of skeletal muscle, chronic inflammation of those muscles – which include those found in the limbs – can result in significant physical impairment.
Apple or pear shape is not main culprit to heart woes -- it's liver fat
For years, pear-shaped people who carry weight in the thighs and backside have been told they are at lower risk for high blood pressure and heart disease than apple-shaped people who carry fat in the abdomen. But new findings from nutrition researchers at Washington University School of Medicine in St. Louis suggest body-shape comparisons don't completely explain risk.
A spoonful of sugar?
The widespread problem of children failing to take their medication for a range of life-threatening illnesses is to be tackled as part of a new university research project.
New study identifies link between Alzheimer's disease biomarkers in healthy adults
A study published in the November issue of the Journal of Alzheimer's Disease provides an insight into normal, physiological levels and association between proteins involved in development of Alzheimer's disease. A group of scientists and physicians from the University of Washington and Puget Sound Veterans' Affairs Health Care System in Seattle, in collaboration with groups from the University of Pennsylvania and the University of California San Diego, performed a study in cognitively normal and generally healthy adults, from young to old (age range 21-88 years), of both genders, measuring levels of different brain-derived molecules associated with Alzheimer's disease.
Secreted protein sends signal that fat is on the way
After you eat a burger and fries or other fat-filled meal, a protein produced by the liver may send a signal that fat is on the way, suggests a report in the December issue of the journal Cell Metabolism, a Cell Press publication.
If Cheaper is Better to Treat Hypertension Then Why Aren't More Patients Prescribed Low Cost Diuretics
(PhysOrg.com) -- An independent study comparing a low cost diuretic to ACE inhibitors, calcium blockers and alpha blockers for the treatment of high blood pressure and hypertension was sponsored by the National Heart, Lung and Blood Institute. The study entitled Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was conducted for the period of 1994 to 1998 with the last follow-up visit in March, 2002.

AAT protein restores blood glucose in type 1 diabetes model

Related stories:

News discussion: